Marlins demote former Rookie of the Year winner Chris Coghlan to Triple-A

3 Comments

For the second straight season Chris Coghlan has been sent down to Triple-A, as the Marlins demoted the former Rookie of the Year winner yesterday after he hit just .118 in 36 plate appearances as a bench player.

Coghlan took the news well, telling Manny Navarro of the Miami Herald that the demotion wasn’t as tough on him as last year and “it’s going to be good for me in the long run because I get to go down and play every day and you never know what can happen.”

Coghlan has fallen so far out of the Marlins’ plans at this point that he may be better off getting an opportunity to start over elsewhere, although there’s little incentive for Miami to trade him with his value at an all-time low.

Since being named Rookie of the Year in 2009 on the strength of a .321 batting average Coghlan has hit just .245 with a .675 OPS in 175 games. He’s defensively versatile in the sense that he has experience at multiple positions, but isn’t actually a good defender at any of them and even Coghlan’s minor-league production was lacking last season.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.